From the Guidelines
The recommended dose and frequency of Robaxin (Methocarbamol) is 1000-1500 mg every 4-6 hours, with a maximum dose of ≤ 4 g/day [@\1@].
Dosing Regimens
- The dosing regimens for Methocarbamol vary, but the most commonly recommended dose is 400-800 mg IV every 6 hours or 400 mg PO every 4 hours [@\1@].
- For oral administration, the starting dose is typically 100 mg PO three times daily, with a maintenance dose of 900-3600 mg/day in 3 divided doses [@\1@].
- The maximum dose for IV administration is ≤ 4 g/day, while the maximum dose for PO administration is ≤ 2.4 g/day or ≤ 1200 mg/day for some regimens [@\1@].
Administration
- Methocarbamol can be administered orally or intravenously, with IV administration typically involving infusion over > 30 minutes [@\1@].
- The choice of administration route and dosing regimen may depend on the individual patient's needs and medical condition.
From the FDA Drug Label
DOSAGE AND ADMINISTRATION For Intravenous and Intramuscular Use Only. Total adult dosage should not exceed 30 mL (3 vials) a day for more than 3 consecutive days except in the treatment of tetanus. For the relief of symptoms of moderate degree, one dose of 1 gram (one 10 mL vial) may be adequate. For the severest cases or in postoperative conditions in which oral administration is not feasible, additional doses of 1 gram may be repeated every 8 hours up to a maximum of 3 g/day for no more than 3 consecutive days.
The recommended dose and frequency of Robaxin (Methocarbamol) is:
- 1 gram (one 10 mL vial) for moderate symptoms, which may be adequate as a single dose
- 1 gram repeated every 8 hours, up to a maximum of 3 g/day for no more than 3 consecutive days for severe cases or postoperative conditions 1
From the Research
Recommended Dose and Frequency of Robaxin (Methocarbamol)
The recommended dose and frequency of Robaxin (Methocarbamol) are not explicitly stated in the provided studies. However, the following information can be gathered:
- The study 2 mentions that methocarbamol was administered orally for up to 8 days, but treatment was discontinued as soon as a pain-free state was achieved.
- The study 3 reports that patients received a 4-week treatment with methocarbamol, with significant improvements in pain intensity, pain-related disability, and quality of life.
- The study 4 states that the mean dose of methocarbamol over the 4-week evaluation period was 2390.4 ± 1980 (3000) mg.
Key Findings
- Methocarbamol is an effective treatment for acute low back pain and muscle-related low/back pain 2, 3.
- Methocarbamol is well-tolerated, with few adverse events reported 2, 3, 4.
- The optimal dose and frequency of methocarbamol may vary depending on the individual patient and the specific condition being treated.
Adverse Events
- Mild side effects such as drowsiness, mild weakness, and excessive perspiration have been reported 5.
- No severe adverse effects were observed in the study 2.
- The study 4 reports a significantly lower number of patients treated with methocarbamol experienced drug-related adverse events compared to those treated with oral long-acting opioid analgesics.